In preparing this update, the committee was guided by the following principles:
(1) Changes in recommendations and levels of evidence were made either because of new randomized trials or because of the accumulation of new clinical evidence and the development of clinical consensus. (2) The committee is cognizant of the healthcare, logistic, and financial implications of recent trials and factored in these considerations in arriving at the class level of certain recommendations. (3) Minor wording changes were made to render some recommendations more precise. (4) The committee wishes to re-emphasize that the recommendations in the guideline apply to most patients but may require modification by existing situations that only the primary treating physician can evaluate properly. (5) All of the listed recommendations for implantation of a device presume the absence of inciting causes that may be eliminated without detriment to the patient (eg, nonessential drug therapy). (6) The committee endeavored to maintain consistency of recommendations in this and other previously published guidelines. In the section on atrioventricular (AV) block associated with acute myocardial infarction (AMI), the recommendations follow closely those in the ACC/AHA Guideline for the Management of Patients With Acute Myocardial Infarction. 1 However, given the rapid evolution of pacemaker/ICD science, it has not always been possible to maintain consistency with other guidelines. An example of such a discrepancy can be found in Section I-H, in which the recommendation for biventricular pacing in selected patients with heart failure has been listed under Class IIa, whereas in the ACC/AHA Guideline for the Evaluation and Management of Chronic Heart Failure in the Adult, 2 biventricular pacing is cited as an investigational procedure.
The ACC/AHA classifications I, II, and III are used to summarize indications as follows:
Class I: Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.
Class II:
Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.
IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.
IIb:
Usefulness/efficacy is less well established by evidence/opinion.
Class III:
Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful.
The weight of the evidence was ranked highest (A) if the data were derived from multiple randomized clinical trials that involved large numbers of patients and intermediate (B) if the data were derived from a limited number of randomized trials that involved small numbers of patients or from careful analyses of nonrandomized studies or observational registries. A lower rank (C) was given when expert consensus was the primary basis for the recommendation.
1. Third-degree AV block at any anatomic level, associated with any one of the following conditions:
a. Bradycardia with symptoms presumed to be due to AV block. (Level of Evidence: C) b. Arrhythmias and other medical conditions that require drugs that result in symptomatic bradycardia. (Level of Evidence: C) c. Documented periods of asystole greater than or equal to 3.0 seconds or any escape rate less than 40 beats per minute (bpm) in awake, symptom-free patients. (Level of Evidence: B, C) d. After catheter ablation of the AV junction. (Level of Evidence: B, C) There are no trials to assess outcome without pacing, and pacing is virtually always planned in this situation unless the operative procedure is AV junction modification.
e. Postoperative AV block that is not expected to resolve. (Level of Evidence: C)
Third-degree and advanced second-degree AV block at any anatomic level, associated with any one of the following conditions: a. Bradycardia with symptoms (including heart failure) presumed to be due to AV block. (Level of Evidence: C) b. (No change) c. Documented periods of asystole greater than or equal to 3.0 seconds (3) or any escape rate less than 40 beats per minute (bpm) in awake, symptom-free patients (4,5). (Levels of Evidence: B, C)
d. After catheter ablation of the AV junction. (Levels of Evidence: B, C) There are no trials to assess outcome without pacing, and pacing is virtually always planned in this situation unless the operative procedure is AV junction modification (6,7). e. Postoperative AV block that is not
The changes emphasize the importance of the site of the block and introduce "advanced second-degree AV block" as a class I indication. This recommendation is based on several observational studies and is supported by a wealth of clinical experience. The narrative portion of this section also emphasizes that the site of origin of the escape rhythm in cases of advanced AV block is as important (or more important) than the escape rate itself.
In recommendation 1a, heart failure is specifically introduced as a major symptom that merits consideration when dealing with AV block-induced bradycardia.
In recommendation 1e, "cardiac surgery" was added to specifically define the situation(s) in which this recommendation applies.
Recommendation 1f has been amplified to indicate that pacing therapy is recommended in patients with neuromuscular diseases and expected to resolve after cardiac surgery. (Level of Evidence: C) (8-10) f. Neuromuscular diseases with AV block, such as myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb's dystrophy (limb-girdle), and peroneal muscular atrophy, with or without symptoms, because there may be unpredictable progression of AV conduction disease.
(Level of Evidence: B) (11-17)
third-degree AV block whether or not they are symptomatic, in view of the unpredictable progression of AV conduction in this group of diseases.
2. Second-degree AV block regardless of type or site of block, with associated symptomatic bradycardia. (Level of Evidence: B) (18) No change
Class IIa Class IIa Class IIa
1. Asymptomatic third-degree AV block at any anatomic site with average awake ventricular rates of 40 bpm or faster. (Level of Evidence: B, C)
Asymptomatic third-degree AV block at any anatomic site with average awake ventricular rates of 40 bpm or faster especially if cardiomegaly or left ventricular (LV) dysfunction is present. (Levels of Evidence: B, C)
This change introduces the concept that cardiomegaly and LV dysfunction are important considerations in the decision-making process to implant a pacemaker in asymptomatic patients with third-degree AV block and otherwise "acceptable" heart rates.
Asymptomatic type II second-degree AV block. (Level of Evidence: B)

Asymptomatic type II second-degree AV block with a narrow QRS. When type II second-degree AV block occurs with a wide QRS, pacing becomes a Class I recommendation (see next section regarding Pacing for Chronic Bifascicular and Trifascicular Block). (Level of Evidence: B) (19,20)
Based on reports and clinical experience, the change in this recommendation calls attention to the site of the block and emphasizes that a wide QRS complex in patients with type II second-degree AV block suggests the presence of diffuse conduction system disease and constitutes an indication for pacing therapy even in asymptomatic patients.
3. Asymptomatic type I second-degree AV block at intra-or infra-His levels found incidentally at electrophysiological study performed for other indications. Wording change to clarify that symptoms resulting from first-or second-degree AV block may be similar to those of the pacemaker syndrome rather than suggestive of this syndrome per se.
Class IIb Class IIb Class IIb
1. Marked first-degree AV block (more than 0.30 seconds) in patients with LV dysfunction and symptoms of congestive heart failure in whom a shorter AV interval results in hemodynamic improvement, presumably by decreasing left atrial filling pressure. (Level of Evidence: C) (24) No change
Neuromuscular diseases such as myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb's dystrophy (limb-girdle), and peroneal muscular atrophy with any degree of AV block (including first-degree AV block) with or without symptoms, because there may be unpredictable progression of AV conduction disease. (Level of Evidence: B) (11-17)
New recommendation for pacemaker insertion in patients with neuromuscular diseases and second-or first-degree AV block, ie, lesser degrees of AV block than those listed under Class I recommendation 1f. Addition of hypoxia occurring during periods of sleep apnea as a cause of transient AV block that is unlikely to recur once sleep apnea syndrome has been treated. 
SECTION I-B: PACING FOR CHRONIC BIFASCICULAR AND TRIFASCICULAR BLOCK
Recommendations for Permanent Pacing in Chronic Bifascicular and Trifascicular Block
Class I Class I Class I
Alternating bundle-branch block. (Level of Evidence: C) (37)
New Class I recommendation that adds alternating bundle branch block to the manifestations of fascicular block that indicate pacing therapy. This recommendation was not explicitly stated in the previous version.
Class IIa Class IIa Class IIa
1. Syncope not proved to be due to AV block when other likely causes have been excluded, specifically ventricular tachycardia (VT). (Level of Evidence: B)
Syncope not demonstrated to be due to AV block when other likely causes have been excluded, specifically ventricular tachycardia (VT). (Level of Evidence: B) (38-55)
Change of "proved" to "demonstrated" because it may be very difficult to prove the cause of syncope.
2. Incidental finding at electrophysiological study of markedly prolonged HV interval (greater than or equal to 100 milliseconds) in asymptomatic patients. (Level of Evidence: B) (47) No change 3. Incidental finding at electrophysiological study of pacing-induced infra-His block that is not physiological. (Level of Evidence: B) (54) No change
Class IIb
Class IIb Class IIb
Neuromuscular diseases such as myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb's dystrophy (limb-girdle), and peroneal muscular atrophy with any degree of fascicular block with or without symptoms, because there may be unpredictable progression of AV conduction disease. (Level of Evidence: C) (11-17)
New Class IIb recommendation for pacing therapy in patients with neuromuscular diseases and fascicular block. Clinical experience suggests that progression of AV conduction disturbance is unpredictable, and high-grade AV block can develop even in asymptomatic patients with these diseases. The change of awake heart rate from 30 to 40 bpm was made on the basis of clinical experience and provides the clinician more flexibility to consider pacing in patients with suspected sinus node dysfunction, in whom a firm diagnosis cannot be made.
Class III Class III Class III
1. Sinus node dysfunction in asymptomatic patients, including those in whom substantial sinus bradycardia (heart rate less than 40 bpm) is a consequence of long-term drug treatment.
No change 2. Sinus node dysfunction in patients with symptoms suggestive of bradycardia that are clearly documented as not associated with a slow heart rate.
No change
3. Sinus node dysfunction with symptomatic bradycardia due to nonessential drug therapy.
SECTION I-E: PREVENTION AND TERMINATION OF TACHYARRHYTHMIAS BY PACING
Recommendations for Permanent Pacemakers That Automatically Detect and Pace to Terminate Tachycardias
Class I Class I Class I
1. Symptomatic recurrent supraventricular tachycardia that is reproducibly terminated by pacing after drugs and catheter ablation fail to control the arrhythmia or produce intolerable side effects. (Level of Evidence: C)
This recommendation was downgraded from Class I to Class IIa. Committee consensus was that it is highly unlikely that treatment with drugs and/or ablation therapy would fail to control supraventricular tachycardia (SVT) (see below).
Symptomatic recurrent sustained VT as part of an automatic defibrillator system. (Level of Evidence: B)
Deleted because this indication is dealt with in the ICD section.
Class IIa
Class IIa Class IIa
Symptomatic recurrent SVT that is reproducibly terminated by pacing in the unlikely event that catheter ablation and/or drugs fail to control the arrhythmia or produce intolerable side effects. (Level of Evidence: C) (70-74)
The rewording of this previously Class I recommendation is intended to convey that ablation and/or drugs are effective therapies for SVT, and it is unlikely that pacing therapy will be required.
Class IIb
Class IIb Class IIb 
Prevention of symptomatic, drug-refractory, recurrent atrial fibrillation in patients with coexisting sinus node dysfunction. (Level of Evidence: B) (79-81)
This recommendation was revised and the level of evidence upgraded to "B" to reflect the available information. Several studies suggest that in some patients with recurrent atrial fibrillation and coexisting sinus node dysfunction, atrial-based pacing reduces the recurrence rate of this arrhythmia.
Class III Class III Class III
1. Frequent or complex ventricular ectopic activity without sustained VT in the absence of the long-QT syndrome.
No change 2. Long-QT syndrome due to reversible causes.
Torsade de Pointes VT due to reversible causes.
Wording change because the arrhythmia is the Torsade de Pointes VT and not the long-QT syndrome.
SECTION I-F: PACING IN HYPERSENSITIVE CAROTID SINUS AND NEUROCARDIOGENIC SYNCOPE
Recommendations for Permanent Pacing in Hypersensitive Carotid Sinus Syndrome and Neurocardiogenic Syncope
Class I Class I Class I
1. Recurrent syncope caused by carotid sinus stimulation; minimal carotid sinus pressure induces ventricular asystole of more than 3-second duration in the absence of any medication that depresses the sinus node or AV conduction. (Level of Evidence: C) (82, 83) No change
Class IIa
Class IIa Class IIa Deleted from this section and more appropriately placed in the Sinus Node Dysfunction section as Recommendation #2, Class IIa.
Significantly symptomatic and recurrent neurocardiogenic syncope associated with bradycardia documented spontaneously or at the time of tilt-table testing. (Level of Evidence: B) (84-87)
This recommendation was added to reflect the results of trials that have demonstrated that pacing therapy is effective in cases of vasovagal syncope associated with episodes of spontaneous or provoked bradycardia. The level of evidence was set to "B" to reflect published trials.
Recommendation 2002 New or Revised Recommendations Comments
Class IIb Class IIb Class IIb
1. Neurally mediated syncope with significant bradycardia reproduced by a head-up tilt with or without isoproterenol or other provocative maneuvers. (Level of Evidence: B)
Deleted
Class III
Class III Class III 1. A hyperactive cardioinhibitory response to carotid sinus stimulation in the absence of symptoms.
A hyperactive cardioinhibitory response to carotid sinus stimulation in the absence of symptoms or in the presence of vague symptoms such as dizziness, lightheadedness, or both. (Level of Evidence: C)
This Class III recommendation replaces the prior recommendations #1 and #2 for the sake of simplicity.
2.
A hyperactive cardioinhibitory response to carotid sinus stimulation in the presence of vague symptoms such as dizziness, lightheadedness, or both. This becomes #2.
Situational vasovagal syncope in which avoidance behavior is effective. (Level of Evidence: C)
This becomes #3.
SECTION I-G: PACING IN CHILDREN, ADOLESCENTS, AND PATIENTS WITH CONGENITAL HEART DISEASE
Recommendations for Permanent Pacing in Children, Adolescents, and Patients With Congenital Heart Disease
Class I Class I Class I
1. Advanced second-or third-degree AV block associated with symptomatic bradycardia, congestive heart failure, or low cardiac output. (Level of Evidence: C)
Advanced second-or third-degree AV block associated with symptomatic bradycardia, ventricular dysfunction, or low cardiac output. (Level of Evidence: C)
This recommendation was reworded, substituting "ventricular dysfunction" for "congestive heart failure" to reflect accumulating clinical experience that ventricular dysfunction adversely affects the prognosis of patients with congenital third-degree AV block even in the absence of overt heart failure. 
Sinus node dysfunction with correlation of
Postoperative advanced second-or third-degree AV block that is not expected to resolve or persists at least 7 days after cardiac surgery. (Level of Evidence: B, C (89,90)
Reworded recommendation to specify that AV block that persists for more than 7 days after cardiac surgery is unlikely to resolve and is best treated with the implantation of a pacemaker. The change was made because of accumulating clinical experience and published studies demonstrating adverse prognosis in such patients who did not receive a permanent pacemaker for rate support.
Congenital third-degree AV block with a wide QRS escape rhythm or ventricular dysfunction. (Level of Evidence: B)
Congenital third-degree AV block with a wide QRS escape rhythm, complex ventricular ectopy, or ventricular dysfunction. (Level of Evidence: B) (91-93)
"Complex ventricular ectopy" was added to the other elements of this recommendation to reflect growing experience that in this setting, prognosis is adversely affected by such ectopy in the absence of rate support by a permanent pacemaker. 
Congenital third-degree AV block beyond the first year of life with an average heart rate less than 50 bpm, abrupt pauses in ventricular rate that are two or three times the basic cycle length, or associated with symptoms due to chronotropic incompetence. (Level of Evidence: B) (99)
Rewording of this recommendation to include symptoms due to chronotropic incompetence and abrupt pauses in ventricular rate in young patients with third-degree AV block after the first year of life. These events have been found to affect prognosis in patients with asymptomatic congenital third-degree AV block. 
Long-QT
Asymptomatic sinus bradycardia in the child with complex congenital heart disease with resting heart rate less than 40 bpm or pauses in ventricular rate more than 3 seconds. (Level of Evidence: C)
The resting heart rate was changed from 35 to 40 bpm on the basis of clinical experience and expert consensus.
Patients with congenital heart disease and impaired hemodynamics due to sinus bradycardia or loss of AV synchrony. (Level of Evidence: C)
New recommendation for pacing in children with impaired hemodynamics as a result of sinus bradycardia or loss of AV synchrony. Clinical experience has accumulated that indicates that children with congenital heart disease and hemodynamic impairment as a result of these conditions have unfavorable prognosis if not paced.
Class IIb
Class IIb Class IIb Modification of this recommendation to include "young adults" with congenital third-degree AV block by clinical consensus.
3. Asymptomatic sinus bradycardia in the adolescent with congenital heart disease with resting heart rate less than 35 bpm or pauses in ventricular rate more than 3 seconds. (Level of Evidence: C)
Asymptomatic sinus bradycardia in the adolescent with congenital heart disease with resting heart rate less than 40 bpm or pauses in ventricular rate more than 3 seconds. (Level of Evidence: C)
Change of resting heart rate from 35 to 40 bpm as a result of clinical experience and expert consensus.
Neuromuscular diseases with any degree of AV block (including first-degree AV block), with or without symptoms, because there may be unpredictable progression of AV conduction disease.
New Class IIb recommendation for pacing in children and adolescents with a neuromuscular disease and any degree of AV block. This is similar to the recommendation for pacing in this situation for adults (Section I-A).
Recommendation 2002 New or Revised Recommendations Comments
Class III Class III Class III
1. Transient postoperative AV block with return of normal AV conduction within 7 days. (Level of Evidence: B)
Transient postoperative AV block with return of normal AV conduction. (Level of Evidence: B) (90,102)
Rewording of this Class III recommendation to eliminate the 7-day window. There is clinical evidence that patients with postoperative AV block who regain normal AV conduction at any time have generally favorable prognosis without pacing. Modification of this recommendation to clarify that pacing therapy is not indicated in symptomatic ischemic cardiomyopathy when the patient can be treated with revascularization therapy. : A) (141-143) No substantive change. Level of evidence raised from "B" to "A" as a result of newly published studies.
SECTION I-H: PACING IN SPECIFIC CONDITIONS (continued)
CARDIAC TRANSPLANTATION
Pacing Recommendations After Cardiac Transplantation
Class I Class I Class I
Spontaneous sustained VT in patients who do not have structural heart disease that is not amenable to other treatments. (Level of Evidence: C)
New recommendation for ICD implantation in patients with sustained VT and structurally normal hearts when alternative treatments have failed (See #2 above)
Class IIa Class IIa Class IIa
Patients with LV ejection fraction of less than or equal to 30%, at least one month post myocardial infarction and three months post coronary artery revascularization surgery. (Level of Evidence: B) (159)
New recommendation for implantation of an ICD prophylactically in the defined population. This recommendation is promulgated as a result of a randomized trial that demonstrated a 5.6% absolute risk reduction and a 31% relative risk reduction for death in the patient group receiving an ICD. The committee consensus was that further risk stratification of the referenced population might better define the benefit of an ICD in such patients. The reader should review the discussion regarding this recommendation in the full-text guideline on the ACC, AHA, and NASPE web sites.
Class IIb
Class IIb Class IIb New recommendation for ICD implantation in patients with the Brugada syndrome and syncope or family history of sudden cardiac death. Several reports suggest that ICD therapy in patients with this syndrome is effective in preventing sudden death. 
Syncope in patients with advanced structural heart disease in which thorough invasive and noninvasive investigation has failed to define a cause. (Level of Evidence: C)
New recommendation based on clinical experience and expert consensus. Patients with advanced structural heart disease and syncope of undetermined etiology despite thorough investigation are likely to have an arrhythmic cause of the syncope and thus may benefit from ICD insertion. Changed to address the issue of many patients with structural heart disease who experience cardiac arrest in the setting of abnormal electrolytes. Such patients may still be at risk for recurrent arrhythmic events and may still benefit from ICD therapy. 
Class III Class III
Significant psychiatric illnesses that may
